Navigation Links
Spike in Use of Popular Reflux Drug to Treat Infants Causes Alarm
Date:5/3/2010

Reglan, metoclopramide never approved for use in infants

HOUSTON, May 3 /PRNewswire-USNewswire/ -- Recently, researchers have observed a disturbing trend in neonatal units across the country:  doctors prescribing Reglan -- also known by its generic name, metoclopramide -- to treat premature infants. This alarming development has raised serious concerns from many consumer safety advocates, particularly because the drug was never approved for use in infants.

Reglan (metoclopramide) was approved for short term use – no longer than three months – by the Food & Drug Administration in 1979 to treat various gastrointestinal disorders.  But in 2009, the FDA issued a black box warning, the strongest of its kind, for the drug and its generic forms, stating that the medication had "been linked to tardive dyskinesia."  In fact, Reglan (metoclopramide) has been identified as the leading cause of TD among patients with the disorder in the United States.

The increase in its use in neonatal units began about a decade ago, when the only motility agent approved for use in infants was pulled from the market for safety concerns.  It has continued to grow each year.  While those at highest risk of developing TD are women and the elderly, there are very serious concerns about the safety of treating babies with Reglan (metoclopramide), as there has never been any significant research done on the drug's effects on infant populations.  

"Although the FDA issued its black box warning last year," said Scott Nabers, of Blizzard, McCarthy & Nabers, which represents dozens of patients disabled by Reglan, "many doctors and patients are still not aware of the significant risks associated with its use.  Because Reglan has been on the market for over 30 years, many physicians assume the drug is safe and prescribe it for various off-label uses.  Perhaps the most troubling of these is its use to treat premature babies whose bodies are already extremely frail."

Blizzard, McCarthy & Nabers recently launched the website ReglanJustice.com to provide consumers with critical information about the risks associated with Reglan (metoclopramide).

Blizzard, McCarthy & Nabers, LLP, one of the nation's leading pharmaceutical litigation firms, represents thousands of clients harmed by dangerous drugs and medical devices and has taken on some of the world's largest corporations, including Bristol-Myers, GlaxoSmithKline, Merck, Pfizer and Dow Chemical. 


'/>"/>
SOURCE Blizzard, McCarthy & Nabers, LLP
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Senate Rejects Bulk Imports of Medicine from Canada, but Personal Importation Remains a Popular Option for U.S. Citizens
2. VerifyNow(R) System Highlighted in POPular Study Comparing Platelet Reactivity Tests
3. Popular Breast Cancer Drug Used with Certain Antidepressants Puts New Jersey Women at Risk
4. Research: Popular Diabetes Medications Associated with Increase in Bone Fractures
5. New Studies Show Popular Heartburn Medications Moderate the Effect of Taking Widely Prescribed Heart Drug
6. Clinical Trial Shows Cardiovascular Benefits of Rooibos, Popular Antioxidant Herbal Tea from South Africa
7. Popular Energy Drinks Cause Tooth Erosion
8. Recent Studies Suggest Popular Diet Pill Relacore Reduces Acne Breakouts
9. An Open Letter to Parents, Students, School Administrators, & Health Care Officials from Soapopular(R)
10. New Incision-Less Procedure for REFLUX - Experts Consider it to Be Gold Standard for REFLUX
11. Medical World Recognises New Therapy for Reflux Babies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/7/2017)... , June 7, 2017  Novavax, Inc., (Nasdaq: ... two Phase 2 trials of its RSV F protein recombinant ... bearing age have been published in the journal ... been shared in prior scientific conferences). The Company previously announced ... 2014. Novavax is developing the RSV F Vaccine with the ...
(Date:6/5/2017)... -- The Cincinnati location of Diplomat ... DPLO), has been awarded a Top Workplaces 2017 ... are based on an employee survey administered by WorkplaceDynamics, LLC, ... The survey measures several aspects of workplace culture, including alignment, ... ...
(Date:6/3/2017)... , June 3, 2017  Eli Lilly ... announced that results from the Phase 3 MONARCH ... (CDK)4 & 6 inhibitor, in combination with fulvestrant, ... with fulvestrant alone in women with hormone-receptor-positive (HR+), ... breast cancer who have relapsed or progressed after ...
Breaking Medicine Technology:
(Date:6/26/2017)... ... June 26, 2017 , ... If the devil is in ... red these days. According to recent estimates, 75 – 80% of the medical ... Some studies point to Electronic Health Records (EHR) with automated features designed to ...
(Date:6/25/2017)... CA (PRWEB) , ... June 24, 2017 , ... Create a feel-good lyric music video ... above footage and sound in the timeline and write in the lyrics to any song. ... flying back out. Each line of the text can be added modularly for optimal control. ...
(Date:6/25/2017)... , ... June 25, 2017 , ... With a heatwave currently bearing down on Northern ... out at the pool. Being swimsuit ready is easy with laser hair removal. , ... again can be a burdensome routine when all you want to do is get out, ...
(Date:6/24/2017)... ... June 24, 2017 , ... Dr. ... 217 Portion Road in Lake Ronkonkoma, Dental365 offers patients high-quality and affordable routine ... visits to the dentist fit into their patients’ busy lifestyles. Dental365 also gladly ...
(Date:6/23/2017)... ... June 23, 2017 , ... "The Better Care Reconciliation ... significant harm to people with all chronic conditions, including mental illnesses, while increasing ... place the Affordable Care Act (ACA) requirement that insurers cover pre-existing conditions, it ...
Breaking Medicine News(10 mins):